Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type.
Tumor necrosis factor-alpha (TNF-alpha) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-alpha, rendering it inactive. A recent clinical trial has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.
Newland
Meggan R
MR
Department of Dermatology and Cutaneous Surgery, University of Miami, 1444 NW 9th Avenue, Miami, FL 33136, USA. dermatology.department@hcahealthcare.com
Weinstein
Andrew
A
Kerdel
Francisco
F
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D000069285:Infliximab; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D011930:Reaction Time / Q000502:physiology; D012720:Severity of Illness Index; D013997:Time Factors
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab